Current Research Interests:
Dr. Panageas is involved in the analysis of cluster correlated data primarily in the context of volume-outcome studies. She is currently involved in the assessment of appropriate endpoints for trials involving brain tumor patients and is evaluating the effects of interval censored data in phase II and III clinical trials with progression-free survival as a primary endpoint. Dr. Panageas is involved with the Clinical Immunology, Leukemia, and Neurology Services to design and analyze prospective and retrospective studies to evaluate treatment strategies including immuno-therapies, explore various biomarkers, develop prediction models and develop models to estimate the risk of developing distant metastasis or local tumor. She continues to serve as the primary statistician for the NIH program project entitled "Biological Approaches to the Treatment of Cancer".
Selected Bibiography:
- Begg MD, Panageas KS. Interval estimation of the common odds ratio from k(2x2) tables under cluster sampling. Statistics in Medicine 1999;18:1087-1100.
- Mazumdar M, Fazzari M, Panageas KS. A standardization method to adjust for the effect of patient selection in phase II clinical trials. Statistics in Medicine 2001;20: 883-892.
- Panageas KS, Smith A, Gonen M, Chapman PB. An optimal two‑stage phase II design utilizing complete and partial response information separately. Controlled Clinical Trials 2002;23: 355-366.
- Satagopan JM, Panageas KS. A statistical perspective on gene expression data analysis. Statistics in Medicine 2003;22:482-499.
- Panageas KS, Schrag D, Riedel E, Bach PB, Begg CB. The effect of clustering on the association of procedure volume and surgical outcomes. Annals of Internal Medicine 2003;139:658-65.
